The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results

The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results

Human epidermal growth factor receptor 2 (HER2), coded by the proto-oncogene <i>ERBB</i>, is known to be mutated or amplified in various malignant diseases, and many HER2-targeted therapies (including monoclonal antibodies and low-molecular-weight tyrosine kinase inhibitors) have been in...

Full description

Bibliographic Details
Main Author: Kenji Nakano
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:International Journal of Molecular Sciences
Subjects:
osteosarcoma
targeted therapy
HER2
trastuzumab deruxtecan
antibody–drug conjugate
CAR-T
Online Access:https://www.mdpi.com/1422-0067/24/23/16823

Internet

https://www.mdpi.com/1422-0067/24/23/16823

Similar Items